Legato Capital Management LLC Invests $85,000 in InfuSystem Holdings, Inc. (NYSE:INFU)

Legato Capital Management LLC purchased a new position in shares of InfuSystem Holdings, Inc. (NYSE:INFU) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 10,014 shares of the company’s stock, valued at approximately $85,000.

A number of other hedge funds also recently modified their holdings of the business. BNP Paribas Financial Markets grew its holdings in shares of InfuSystem by 66.4% during the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after buying an additional 1,626 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of InfuSystem during the third quarter worth about $87,000. JPMorgan Chase & Co. grew its holdings in shares of InfuSystem by 74.1% during the third quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company’s stock worth $104,000 after buying an additional 6,623 shares in the last quarter. Barclays PLC grew its holdings in shares of InfuSystem by 300.5% during the third quarter. Barclays PLC now owns 28,597 shares of the company’s stock worth $192,000 after buying an additional 21,457 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its holdings in shares of InfuSystem by 28.0% during the third quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company’s stock worth $223,000 after buying an additional 7,295 shares in the last quarter. Institutional investors and hedge funds own 71.13% of the company’s stock.

InfuSystem Stock Up 1.5 %

INFU stock opened at $8.12 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The company has a 50 day moving average of $8.23. The company has a market capitalization of $172.63 million, a P/E ratio of 135.36 and a beta of 1.53. InfuSystem Holdings, Inc. has a twelve month low of $5.74 and a twelve month high of $9.97.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th.

Insider Buying and Selling at InfuSystem

In other InfuSystem news, CEO Richard Dilorio sold 5,398 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $8.87, for a total value of $47,880.26. Following the completion of the transaction, the chief executive officer now directly owns 416,659 shares in the company, valued at $3,695,765.33. This trade represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.20% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.